摘要
目的:观察注射用黄芪多糖在弥漫大B细胞淋巴瘤(DLBCL)治疗中的辅助作用。方法:采用病例对照的研究方法,将76例DLBCL患者随机分为2组,治疗组(黄芪多糖联合化疗组)40例,对照组(单纯化疗组)36例,比较4个疗程化疗结束后患者的不良反应、免疫功能及生活质量情况。结果:治疗组不良反应包括白细胞减少、血红蛋白下降、血小板减少、肝功能损害、神经毒性、心功能损害、乏力的发生例数均小于对照组(P<0.05);治疗组治疗后T细胞亚群中NK细胞明显增高,CD4^+/CD8^+比值增大,免疫功能明显好于对照组(P<0.05);治疗组生活质量优于对照组(P<0.05)。结论:注射用黄芪多糖辅助DLBCL化疗可减轻不良反应的发生,增强患者免疫功能并提高其生活质量。
Objective: To observe the supporting effects of astragalus polysaccharide injection in chemotherapy for diffuse large B-cell lymphoma(DLBCL). Methods: Case-control study method was adopted. A total of 76 DLBCL patients were randomly divided into the treatment group(chemotherapy combined with astragalus polysaccharide, 40 patients) and the control group(chemotherapy, 36 patients). After four cycles of chemotherapy, adverse reactions, immunologic function and quality of life situation of two groups were assessed. Results: The number of cases of occurring adverse reactions in respect of leucopenia, decreased hemoglobin, thrombocytopenia, hepatic dysfunction, neurotoxicity, cardiac dysfunction, fatigue in treatment group were significantly less than those in the control group(P < 0.05). After treatment, NK cells and CD4+/CD8+ were significantly increased(P < 0.05), and the quality of life in the treatment group was better than that in control group(P < 0.05). Conclusion: Astragalus polysaccharide combined with chemotherapy can reduce adverse reactions, enhance immunologic function and improve the quality of life in DLBCL patients.
出处
《中国药物应用与监测》
CAS
2016年第3期137-139,143,共4页
Chinese Journal of Drug Application and Monitoring
基金
浙江省科学技术厅省级公益性技术应用研究计划项目(2014C33159)
关键词
黄芪多糖
弥漫大B细胞淋巴瘤
化疗
不良反应
Astragalus polysaccharide
Diffuse large B-cell lymphoma
Chemotherapy
Adverse reaction
